The Globe and Mail reports in its Friday, Nov. 25, edition that Bruce Linton, founder of Canopy Growth, has made a bet on the legal cannabis market in Germany. A Bloomberg dispatch to the Post reports that Mr. Linton acquired an interest in Munich-based Synbiotic SE when it raised capital last month, the company said in a statement Thursday. Mr. Linton will also become chairman of Synbiotic's newly created advisory board and receive options to buy further shares as compensation for his role. Including these instruments, Mr. Linton could increase his interest in the company to 5 per cent. "I see enormous potential in the European market, particularly in Germany because of the recently announced legalization in Europe's largest economy," Mr. Linton said. Synbiotic, which is focused on medical and dietary cannabis, raised 2.5 million euros ($3.5-million) in a share sale last month. It will use the money to expand at a time that Europe is adopting a relaxed approach to recreational cannabis use. Shares of Synbiotic, which have fallen more than 50 per cent this year for a market value of almost 60 million euros, jumped as much as 7.9 per cent in German trading.